Research progress on portal vein thrombosis in liver cirrhosis

doi:10.3877/cma.j.issn.1674-0793.2024.05.012

Abstract

Abstract:

Portal vein thrombosis (PVT) is a complication of cirrhosis, and its incidence rate is positively correlated with the severity of cirrhosis. Some risk factors related to the occurrence and progression of PVT have been identified. Although the negative impact of fully formed PVT on the surgical outcomes of liver transplant recipients is clear, its impact on the progression of cirrhosis is still uncertain. The PVT treatment plan mainly includes anticoagulants and interventional thrombolysis, which requires specific selection based on the characteristics of each patient’s thrombus. This article summarizes the current progress in the definition, epidemiology, pathophysiology, grading, risk factors, diagnosis, natural history, clinical outcomes, and treatment of non-tumor PVT in liver cirrhosis.

Key words: Liver cirrhosis, Coagulation disorders, Portal hypertension, Portal vein thrombosis, Transjugular intrahepatic portosystemic shunt

Meini Ye, Sijia Liu, Yuwei Zang, Yunjian Liu. Research progress on portal vein thrombosis in liver cirrhosis[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(05): 379-384.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2024.05.012

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2024/V18/I05/379

References 33

[1]	European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202.
[2]	Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2021, 73(1): 366-413.
[3]	中华医学会消化病学分会肝胆疾病分组. 肝硬化门静脉血栓管理专家共识（2020年,上海）[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674.
[4]	Rajani R, Björnsson E, Bergquist A, et al. The epidemiology and clinical features of portal vein thrombosis: A multicentre study[J]. Aliment Pharmacol Ther, 2010, 32(9): 1154-1162.
[5]	Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis[J]. Aliment Pharmacol Ther, 2010, 31(3): 366-374.
[6]	Violi F, Corazza GR, Caldwell SH, et al. Incidence and recurrence of portal vein thrombosis in cirrhotic patients[J]. Thromb Haemost, 2019, 119(3): 496-499.
[7]	Ponziani FR, Zocco MA, Senzolo M, et al. Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up[J]. Transpl Rev(Orlando), 2014, 28(2): 92-101.
[8]	Rodriguez-Castro KI, Porte RJ, Nadal E, et al. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: A systematic review[J]. Transplantation, 2012, 94(11): 1145-1153.
[9]	Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study[J]. Hepatology, 2015, 61(2): 660-667.
[10]	Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation[J]. J Hepatol, 2012, 57(1): 203-212.
[11]	La Mura V, Tripodi A, Tosetti G, et al. Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis[J]. Liver Int, 2016, 36(9): 1322-1330.
[12]	Saugel B, Lee M, Feichtinger S, et al. Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis[J]. J Thromb Thrombol, 2015, 40(1): 54-60.
[13]	Queck A, Carnevale R, Uschner FE, et al. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS[J]. Gut, 2020, 69(8): 1535-1536.
[14]	Xing Y, Tian Y, Jiang Y, et al. A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis[J]. Ann Med, 2022, 54(1): 302-309.
[15]	Yerdel MA, Gunson B, Mirza D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome[J]. Transplantation, 2000, 69(9): 1873-1881.
[16]	Sherman CB, Behr S, Dodge JL, et al. Distinguishing tumor from bland portal vein thrombus in liver transplant candidates with hepatocellular carcinoma: the A-VENA criteria[J]. Liver Transpl, 2019, 25(2): 207-216.
[17]	Giri S, Singh A, Kolhe K, et al. Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis[J]. J Gastroenterol Hepatol, 2023, 38(10): 1710-1717.
[18]	Senzolo M, Sartori TM, Rossetto V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis[J]. Liver Int, 2012, 32(6): 919-927.
[19]	Zhang Y, Xu BY, Wang XB, et al. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2564-2572, e1.
[20]	Maruyama H, Okugawa H, Takahashi M, et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes[J]. Am J Gastroenterol, 2013, 108(4): 568-574.
[21]	Amitrano L, Guardascione MA, Martino R, et al. Hypoxic hepatitis occurring in cirrhosis after variceal bleeding: still a lethal disease[J]. J Clin Gastroenterol, 2012, 46(7): 608-612.
[22]	Zanetto A, Rodriguez-Kastro KI, Germani G, et al. Mortality in liver transplant recipients with portal vein thrombosis- an updated meta-analysis[J]. Transpl Int, 2018, 31(12): 1318-1329.
[23]	Lisman Ton. Treatment of portal vein thrombosis in cirrhosis with anticoagulation--more than meets the eye?[J]. Hepatobiliary Surg Nutr, 2024, 13(2): 321-324.
[24]	Rodriguez-Castro KI, Vitale A, Fadin M, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis[J]. Eur J Gastroenterol Hepatol, 2019, 31(1): 34-42.
[25]	Simonetto DA, Singal AK, Garcia-Tsao G, et al. ACG clinical guideline: disorders of the hepatic and mesenteric circulation[J]. Am J Gastroenterol, 2020, 115(1): 18-40.
[26]	Rodríguez-Castro KI, Senzolo M, Sartori MT. Optimal length of anticoagulant therapy in cirrhotic patients with portal vein thrombosis[J]. Clin Gastroenterol Hepatol, 2012, 10(7): 820-821.
[27]	Cui SB, Shu RH, Yan SP, et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B[J]. Eur J Gastroenterol Hepatol, 2015, 27(8): 914-919.
[28]	Lobo B, Finch C, Howard A, et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia[J]. Thromb Haemost, 2008, 99(1): 208-214.
[29]	Loffredo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and meta-analysis[J]. Gastroenterology, 2017, 153(2): 480-487, e1.
[30]	La Mura V, Braham S, Tosetti G, et al. Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis[J]. Clin Gastroenterol Hepatol, 2018, 16(7): 1146-1152, e4.
[31]	Leader A, Ten Cate V, Ten Cate-Hoek AJ, et al. Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment[J]. Eur J Intern Med, 2020, 77: 86-96.
[32]	Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis[J]. Aliment Pharmacol Ther, 2019, 49(1): 20-30.
[33]	Bianchini M, Cavani G, Bonaccorso A, et al. Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients[J]. Liver Int, 2018, 38(7): 1253-1262.

Please choose a citation manager

Content to export